All Stories

  1. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase ...

    Article • OncoImmunology, August 2017, Taylor & Francis

    Dr Thomas Filleron

  2. Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses

    Article • Statistical Methods in Medical Research, July 2016, SAGE Publications

    Dr Thomas Filleron

  3. Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R

    Article • Computer Methods and Programs in Biomedicine, March 2016, Elsevier

    Dr Thomas Filleron

  4. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

    Article • European Journal of Cancer, March 2016, Elsevier

    Dr Thomas Filleron

  5. Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?

    Article • PLoS ONE, January 2016, PLOS

    Dr Thomas Filleron

  6. Le score de propension, une alternative crédible à la randomisation ?

    Article • Bulletin du Cancer, January 2016, Elsevier

    Dr Thomas Filleron

  7. Body composition and anti-neoplastic treatment in adult and older subjects - A systematic review

    Article • The journal of nutrition health & aging, December 2015, Springer Science + Business Media

    Dr Thomas Filleron

  8. A Systematic Review and Meta-Analysis of Double Venous Anastomosis in Free Flaps

    Article • Plastic & Reconstructive Surgery, December 2015, Wolters Kluwer Health

    Dr Thomas Filleron

  9. What risk of prostate cancer led urologist to recommend prostate biopsies?

    Article • Progrès en Urologie, December 2015, Elsevier

    Dr Thomas Filleron

  10. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

    Article • Quality of Life Research, November 2015, Springer Science + Business Media

    Dr Thomas Filleron

  11. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 -targeted drugs: results from the European EUHER2 cohort

    Article • Annals of Oncology, November 2015, Oxford University Press (OUP)

    Dr Thomas Filleron

  12. What to expect from molecular tools for non-documented pediatric infectious diseases

    Article • Expert Review of Molecular Diagnostics, October 2015, Taylor & Francis

    Dr Thomas Filleron

  13. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials): Table 2.

    Article • Annals of Oncology, October 2015, Oxford University Press (OUP)

    Dr Thomas Filleron, Professor Fernando Schmitt

  14. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

    Article • Journal of Thoracic Oncology, October 2015, Elsevier

    Dr Thomas Filleron

  15. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I–II trial of radiotherapy/tipifarnib combination

    Article • Journal of Neuro-Oncology, July 2015, Springer Science + Business Media

    Dr Thomas Filleron

  16. Prediction of Early Breast Cancer Metastasis from DNA Microarray Data Using High-Dimensional Cox Regression Models

    Article • Cancer Informatics, May 2015, Libertas Academica, Ltd.

    Dr Thomas Filleron

  17. Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma

    Article • BJU International, April 2015, Wiley

    Dr Thomas Filleron

  18. Perception of Lung Cancer among the General Population and Comparison with Other Cancers

    Article • Journal of Thoracic Oncology, March 2015, Elsevier

    Dr Thomas Filleron

  19. Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R

    Article • Computer Methods and Programs in Biomedicine, March 2015, Elsevier

    Dr Thomas Filleron

  20. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

    Article • Annals of Oncology, February 2015, Oxford University Press (OUP)

    Dr Thomas Filleron, Professor Fernando Schmitt

  21. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

    Article • Journal of Clinical Oncology, February 2015, American Society of Clinical Oncology (ASCO)

    Dr Thomas Filleron

  22. Pelvic exenterations for specific extraluminal recurrences in the era of total mesorectal excision: is there still a chance for cure?

    Article • The American Journal of Surgery, February 2015, Elsevier

    Dr Thomas Filleron

  23. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study

    Article • BMC Medical Genomics, January 2015, Springer Science + Business Media

    Professor Gilles Favre, Dr Thomas Filleron

  24. Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: The METAL3 Study

    Article • Contemporary Clinical Trials, January 2015, Elsevier

    Dr Thomas Filleron

  25. Le rôle des cohortes d’expansion dans les essais de phase I en cancérologie : des recommandations du HUB phase I

    Article • Bulletin du Cancer, January 2015, Elsevier

    Dr Thomas Filleron

  26. Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment

    Article • Radiation Oncology, November 2014, Springer Science + Business Media

    Dr Thomas Filleron

  27. Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT

    Article • Annals of Nuclear Medicine, November 2014, Springer Science + Business Media

    Dr Thomas Filleron

  28. Long-term oncological outcome after endoscopic surgery for olfactory esthesioneuroblastoma

    Article • Acta Oto-Laryngologica, November 2014, Taylor & Francis

    Dr Thomas Filleron

  29. Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer

    Article • Strahlentherapie und Onkologie, November 2014, Springer Science + Business Media

    Dr Thomas Filleron

  30. The frontal branch of the facial nerve: can we define a safety zone?

    Article • Surgical and Radiologic Anatomy, October 2014, Springer Science + Business Media

    Dr Thomas Filleron

  31. RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

    Article • Clinical Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  32. Evaluation of the Lactate-to-N-Acetyl-aspartate Ratio Defined With Magnetic Resonance Spectroscopic Imaging Before Radiation Therapy as a New Predictive Marker of the Site of Relapse in Patients With Glioblastoma Multiforme

    Article • International Journal of Radiation Oncology*Biology*Physics, October 2014, Elsevier

    Dr Thomas Filleron

  33. Faisabilité et fiabilité de la cœliochirurgie dans les cancers utérins chez les patientes de poids normal

    Article • Gynécologie Obstétrique & Fertilité, October 2014, Elsevier

    Dr Thomas Filleron

  34. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer

    Article • BJU International, August 2014, Wiley

    Dr Thomas Filleron

  35. Dermatofibrosarcoma protuberans: Margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients

    Article • Annales de Chirurgie Plastique Esthétique, August 2014, Elsevier

    Dr Thomas Filleron

  36. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

    Article • Annals of Oncology, July 2014, Oxford University Press (OUP)

    Dr Thomas Filleron

  37. Place de la radiothérapie dans le traitement conservateur des sarcomes en territoire irradié

    Article • Cancer/Radiothérapie, June 2014, Elsevier

    Dr Thomas Filleron

  38. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

    Article • The Lancet Oncology, March 2014, Elsevier

    Dr Thomas Filleron

  39. Role of radiation therapy in the conservative management of sarcoma within an irradiated field

    Article • European Journal of Surgical Oncology, February 2014, Elsevier

    Dr Thomas Filleron

  40. RhoB Promotes Cancer Initiation by Protecting Keratinocytes from UVB-Induced Apoptosis but Limits Tumor Aggressiveness

    Article • Journal of Investigative Dermatology, January 2014, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  41. Prognostic Relevance of Celiac Lymph Node Involvement in Ovarian Cancer

    Article • International Journal of Gynecological Cancer, January 2014, Wolters Kluwer Health

    Dr Thomas Filleron

  42. Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study

    Article • Health and Quality of Life Outcomes, January 2014, Springer Science + Business Media

    Dr Thomas Filleron

  43. Conventional Versus Automated Implantation of Loose Seeds in Prostate Brachytherapy: Analysis of Dosimetric and Clinical Results

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2013, Elsevier

    Dr Thomas Filleron

  44. Quel niveau de risque incite l’urologue à réaliser des biopsies de la prostate ? Analyse rétrospective et multicentrique française

    Article • Progrès en Urologie, November 2013, Elsevier

    Dr Thomas Filleron

  45. Prognosis and ICU outcome of systemic vasculitis

    Article • BMC Anesthesiology, October 2013, Springer Science + Business Media

    Dr Thomas Filleron

  46. Instant-quality fluorescencein-situhybridization as a new tool forHER2testing in breast cancer: a comparative study

    Article • Histopathology, October 2013, Wiley

    Dr Thomas Filleron

  47. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy

    Article • Human Pathology, October 2013, Elsevier

    Dr Thomas Filleron

  48. Accuracy of intraoperative pathological examination of SLN in cervical cancer

    Article • Gynecologic Oncology, September 2013, Elsevier

    Dr Thomas Filleron

  49. High Endothelial Venule Blood Vessels for Tumor-Infiltrating Lymphocytes Are Associated with Lymphotoxin  -Producing Dendritic Cells in Human Breast Cancer

    Article • The Journal of Immunology, July 2013, The American Association of Immunologists

    Dr Thomas Filleron

  50. Determining the Length of Posttherapeutic Follow-up for Cancer Patients Using Competing Risks Modeling

    Article • Medical Decision Making, June 2013, SAGE Publications

    Dr Thomas Filleron

  51. αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma

    Article • European Journal of Cancer, June 2013, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  52. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties

    Article • Nature Communications, May 2013, Nature

    Dr Thomas Filleron, Dr Marc Etienne Poirot

  53. A large retrospective multicenter study of vaginal melanomas

    Article • Melanoma Research, April 2013, Wolters Kluwer Health

    Dr Thomas Filleron

  54. Breast Imaging: Understanding How Accuracy is Measured When Lesion are the Unit of Analysis

    Article • The Breast Journal, March 2013, Wiley

    Dr Thomas Filleron

  55. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma

    Article • Journal of Hepatology, March 2013, Elsevier

    Dr Thomas Filleron

  56. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials

    Article • European Journal of Cancer, March 2013, Elsevier

    Dr Thomas Filleron

  57. RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor

    Article • January 2013, Springer Science + Business Media

    Professor Gilles Favre, Dr Thomas Filleron

  58. Recurrence risk after Ivor Lewis oesophagectomy for cancer

    Article • Journal of Cardiothoracic Surgery, January 2013, Springer Science + Business Media

    Dr Thomas Filleron

  59. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost

    Article • Radiation Oncology, January 2013, Springer Science + Business Media

    Dr Thomas Filleron

  60. Designing group sequential randomized clinical trials with time to event end points using a R function

    Article • Computer Methods and Programs in Biomedicine, October 2012, Elsevier

    Dr Thomas Filleron

  61. Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice

    Article • International Journal of Gynecological Cancer, October 2012, Wolters Kluwer Health

    Dr Thomas Filleron

  62. Anatomical correlates for category-specific naming of objects and actions: A brain stimulation mapping study

    Article • Human Brain Mapping, September 2012, Wiley

    Dr Thomas Filleron

  63. High endothelial venules (HEVs) in human melanoma lesions

    Article • OncoImmunology, September 2012, Taylor & Francis

    Dr Thomas Filleron

  64. Laparoscopic observation of the diaphragm undersurface in the staging of peritoneal carcinomatosis: comparison of three optical systems

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, September 2012, Elsevier

    Dr Thomas Filleron

  65. Palliative care

    Article • Annals of Oncology, September 2012, Oxford University Press (OUP)

    Dr Thomas Filleron

  66. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics

    Article • Modern Pathology, July 2012, Nature

    Dr Thomas Filleron

  67. Abstract 725: eIF4E/4eBP-1 as predictive factor(s) of response to EGFR targeted drug in head and neck cancer

    Article • Cancer Research, April 2012, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  68. Personalised cancer follow-up: risk stratification, needs assessment or both?

    Article • British Journal of Cancer, April 2012, Nature

    Dr Thomas Filleron

  69. Résections rectosigmoïdiennes cœlioscopiques pour endométriose digestive : résultats chirurgicaux et fonctionnels

    Article • Journal de Gynécologie Obstétrique et Biologie de la Reproduction, April 2012, Elsevier

    Dr Thomas Filleron

  70. Single domain antibodies with VH hallmarks are positively selected during panning of llama (Lama glama) naïve libraries

    Article • Developmental & Comparative Immunology, January 2012, Elsevier

    Professor Gilles Favre, Dr Thomas Filleron

  71. The Prognostic Significance of Lymphovascular Invasion on Biopsy Specimens in Lung Cancer Treated With Definitive Chemoradiotherapy

    Article • Clinical Lung Cancer, January 2012, Elsevier

    Dr Thomas Filleron

  72. Brachytherapy in Lip Carcinoma: Long-Term Results

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2011, Elsevier

    Dr Thomas Filleron

  73. Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer

    Article • Current Clinical Pharmacology, November 2011, Bentham Science Publishers

    Dr Thomas Filleron

  74. Retrospective Analysis of Local Control and Cosmetic Outcome of 147 Periorificial Carcinomas of the Face Treated With Low–Dose Rate Interstitial Brachytherapy

    Article • International Journal of Radiation Oncology*Biology*Physics, November 2011, Elsevier

    Dr Thomas Filleron

  75. Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose

    Article • European Journal of Nuclear Medicine and Molecular Imaging, September 2011, Springer Science + Business Media

    Professor Louis BUJAN, Dr Thomas Filleron

  76. Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer

    Article • Cancer Research, August 2011, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  77. Coregistration of Prechemotherapy PET-CT for Planning Pediatric Hodgkin's Disease Radiotherapy Significantly Diminishes Interobserver Variability of Clinical Target Volume Definition

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2011, Elsevier

    Dr Thomas Filleron

  78. Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

    Article • Cancer Research, April 2011, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  79. Laparoscopic pelvic exenteration for gynaecological malignancy: Is there any advantage?

    Article • Gynecologic Oncology, March 2011, Elsevier

    Dr Thomas Filleron

  80. Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary

    Article • Journal of Gynecologic Oncology, January 2011, Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy (KAMJE)

    Dr Thomas Filleron

  81. Postoperative Radiotherapy in Head and Neck Mucosal Melanoma

    Article • Archives of Otolaryngology - Head and Neck Surgery, December 2010, American Medical Association (AMA)

    Dr Thomas Filleron

  82. An R function to non-parametric and piecewise analysis of competing risks survival data

    Article • Computer Methods and Programs in Biomedicine, October 2010, Elsevier

    Dr Thomas Filleron

  83. Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer

    Article • Clinical Cancer Research, July 2010, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  84. DNA polymeraseθ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability

    Article • Proceedings of the National Academy of Sciences, July 2010, Proceedings of the National Academy of Sciences

    Dr Thomas Filleron

  85. Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis

    Article • Clinical Cancer Research, February 2010, American Association for Cancer Research (AACR)

    Dr Thomas Filleron

  86. Detection of local recurrences of limb soft tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?

    Article • European Journal of Radiology, October 2009, Elsevier

    Dr Thomas Filleron

  87. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics

    Article • Investigational New Drugs, February 2009, Springer Science + Business Media

    Dr Thomas Filleron

  88. Planning Posttherapeutic Oncology Surveillance Visits Based on Individual Risk

    Article • Medical Decision Making, February 2009, SAGE Publications

    Dr Thomas Filleron

  89. Advances in Soil Dynamics Volume 3

    Article • January 2009, American Society of Agricultural and Biological Engineers (ASABE)

    Dr William Becker, Dr Thomas Filleron

  90. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: A study of the REACT working group of ESTRO

    Article • Radiotherapy and Oncology, January 2006, Elsevier

    Dr Thomas Filleron